This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
11 Citations 2 Q&As
Facts about Laminin subunit alpha-1.
Mouse | |
---|---|
Gene Name: | Lama1 |
Uniprot: | P19137 |
Entrez: | 16772 |
Belongs to: |
---|
No superfamily |
LAMA; Laminin A chain; laminin subunit alpha-1; laminin, alpha 1; Laminin-1 subunit alpha; Laminin-3 subunit alpha; S-LAM alpha; S-laminin subunit alpha
Mass (kDA):
338.148 kDA
Mouse | |
---|---|
Location: | 17 E1.1|17 38.8 cM |
Sequence: | 17; |
In this article, we will examine the applications of LuLISA1 as a molecular markers and how it can be utilized on a larger scale. LuLISA1 is cost-effective and is suited to use on a large scale. Here, we will show how it can be used for the broadest range of biological research. Discover its most intriguing applications by reading further. Its versatility will amaze you.
LuLISA1, a revolutionary, luciferin-based diagnostic test is now available. The new system is based upon a novel method of detection for various cancers. Unlike traditional skin-prick assays, LuLISA is cost-effective and swiftly reaching its sensitivity. It can also be used for screening for cancerous cells and tumours. But how does this new tool work?
The technology is based upon the production of a protein known as luciferase in tandem with an antibody fragment derived from a lama. The conjugate is made up of the gene for shrimp Luciferase, that produces light when it is placed in contact with a substrate. The amount of light produced is proportional to the amount of lama antibodies connected to the target. This method can also be used to detect viral proteins.
Initially designed for allergy tests initially, the LuLISA method was later refined to detect weak cancer markers. It was further refined to detect human immunoglobulin types targeting SARS-CoV-2 coronavirus proteins. It was chosen as its target protein after a thorough analysis of different cancer markers. The new test has been employed by researchers at the Institut Pasteur to screen thousands of cancer patients and treat them promptly.
The LuLISA1 system can also be cost-effective. About 20 grams of Luciferin can be made for 60 million tests. This affordable synthetic access opens the door for new bioluminescence-based reporting systems. This technology is suitable to perform a variety of applications, including large-scale population epidemiological studies as well as extensive interactome mapping. The possibilities for luciferin-based systems are endless.
What is it that defines a company to be cost-effective? Cost-effectiveness is, by definition, a strategy that achieves the highest profits at the lowest cost. In this case child-minding services, it is recommended to be offered in areas where demand is high. These facilities should be flexible, with the availability of new child-minding personnel rotating every week. If the government achieves its goal at the lowest cost to taxpayers, it is considered to be cost-effective.
The definition of cost-effectiveness is often confusing. A lot of people don't know the meaning of cost-effectiveness and how it can be applied to their individual needs. Many think that cost-effectiveness means that an intervention is more efficient than the alternatives, but it's not so. This analysis is different from incremental cost-effectiveness analysis. This type of analysis is more real because it is based on an average of all treatments available for a particular disease.
PMID: 3182802 by Sasaki M., et al. Laminin, a multidomain protein. The A chain has a unique globular domain and homology with the basement membrane proteoglycan and the laminin B chains.
PMID: 3267223 by Hartl L., et al. The N-terminus of laminin A chain is homologous to the B chains.
*More publications can be found for each product on its corresponding product page